Uncovering Hidden Opportunities in Healthcare

Why Wait Months for the Healthcare Insights You Needed Yesterday?

AskMED.ai™ Leveraging all available healthcare encounters on 300M+ Americans, 2.5M+ PubMed publications, and Atomo’s proprietary patient-finding models (~80% PPV) — through a powerful chat-based interface built on 30 years of healthcare analytics expertise.

Get My First Question Answered Free

“…and what’s the secret sauce?”

Sandy Carter, Best-selling author, 10 Myths Busted: The Real Impact of AI and Emerging Tech, Forbes Contributor, SXSW Keynote Speaker, and founder Unstoppable Domains
ai-trailblazers

AskMED.ai ™ Wins Industry Recognition

AskMED.ai ™ earned the top spot at the AI Trailblazers SXSW in 2024, selected from over 100 AI startup candidates by a panel of distinguished judges.
Read Article >

What’s hurting your critical decision process

Critical healthcare decisions are hindered by slow, incomplete data, and the lack of tools to fully act on insights.

Hidden Undiagnosed Patients

A staggering proportion of patients with specific diseases or conditions remain either undiagnosed or misdiagnosed. The undiagnosed population can range from 15% to 90%, depending on the disease. This results in:

  • Poorer health outcomes due to delays in treatment.
  • Higher long-term costs for healthcare systems.
  • Complications from misdiagnosis, leading to inappropriate treatments and adverse effects.

Download our peer reviewed paper on our Patient Finding Process

Download Paper (PDF)
The Last Mile

Atomo’s analytics platform leverages real-world data to uncover disparities in patient access and identify populations with unmet medical needs. As demonstrated in peer-reviewed research co-authored by Atomo’s leadership, restricted access to life-saving therapies can significantly increase cardiovascular event rates. These insights drive Atomo’s mission: using advanced analytics to highlight where intervention is most needed—and enabling healthcare systems and BioPharma to act with precision.

This Paper:

  • Was downloaded more than 10,000 times in the first 12 months
  • Was voted by Circulation as on the 5 highest impact papers of the year
  • Resulted in most payers changing their Prior Authorization polices
Download Paper (PDF)
Minutes Not Months

Discover How Top BioPharma Teams Are Shaving 400+ Days Off Their Strategic Timelines

In an industry where speed and precision are everything, BioPharma leaders are turning to AI-driven solutions to outpace the market. This white paper reveals how AskMED.ai™ is revolutionizing executive decision-making with real-time insights.

Download Paper (PDF)
Critical Many vs the Vital Few

Discover how less than 7% of HCPs treat over half of all patients with MSA and orthostatic hypotension—insight you can’t afford to overlook.

Download this white paper to learn how Atomo’s AI pinpoints high-impact providers, helping BioPharma teams reduce outreach waste and accelerate market access.

Download Paper (PDF)

Does this sound familiar?

Diagnostic Challenges

1 in 8 Americans Receives a Misdiagnosis—Many Wait Years for a Correct Diagnosis

Questions we answer

Data Driven Decisions

71% of decisions are made without data likely due to traditional analytics taking too long, forcing leaders to rely on intuition rather than evidence

Resource Optimization

~5% of healthcare practitioners will treat 50% of patients with specific diseases or conditions

Your Instant Engine for Healthcare Intelligence.

Stop waiting. Start knowing.

Introducing your instant engine for healthcare intelligence, patient finding, and practitioner engagement. AskMED.ai leverages generative AI, NIH-validated patient finding models and real-time analysis of healthcare encounter data.

YouFind the Unfindable

Proactively identify undiagnosed and misdiagnosed patients with high precision (~80% PPV) to enable earlier interventions and improve outcomes.

Pinpoint the 'Vital Few'

Instantly locate the highest-impact patients and practitioners driving costs, outcomes, and treatment adoption across 80+ diseases.

Accelerate Decisions Dramatically

Transform analysis timelines from months (90-430 days) to mere minutes or days, saving up to a year on strategic initiatives.

Unify Fragmented Intelligence

Get conversational access to integrated insights from healthcare encounters, medical literature, and proprietary models – all in one place.

Drive Efficiency & Innovation

Empower Biopharma, Health Systems, and Clinicians with the clarity needed to optimize resources at the point of care.

Validated by Science.
Trusted by Healthcare Leaders.

Independently Validated

Atomo has served as a key contributor on over five NIH-funded grants focused on advancing AI-based Patient Finding Models across multiple U.S. health systems. Notably, Atomo is the Principal Investigator on a prestigious award from the National Heart, Lung, and Blood Institute, titled “Finding undiagnosed ATTR-CM patients using AI technology in clinical settings” (Award Number: 1R44HL162443-01A1). This R&D-driven project underscores Atomo’s leadership in applying advanced machine learning to identify high-risk, yet undiagnosed patients—bringing earlier intervention and better outcomes to complex cardiovascular conditions.

Atomo’s NIH Grants

Peer-Reviewed Validation in Major Medical Journals

Over a dozen peer-reviewed publications in major prestigious medical journals, including; The Lancet Digital Health, Nature Digital Medicine, and Circulation.

Our Key Publications

Strategic Partnerships with Multiple Healthcare Stakeholders

Discover how Atomo and AstraZeneca are transforming rare disease diagnosis with AI models already deployed in major U.S. and U.K. health systems.

Download this white paper to see how predictive modeling and real-world data are accelerating time-to-diagnosis and empowering earlier intervention.

Download Paper (PDF)
Questions we answer

Powered by Leading Cloud Technology

AskMED.ai™ leverages the robust and scalable infrastructure of Google Cloud ensuring a powerful and safe platform for delivering rapid healthcare insights.

The Atomo / AskMED.ai Difference

From Months of Waiting to Minutes of Knowing

Traditional Analytics

Insight Speed

90 – 400+ Days

Data Access

Siloed, Manual Queries, Static Reports

Patient Finding
Manual, Slow, Low Accuracy
 
Scope
Limited by Pre-defined Reports
 
Usability

Requires Data Science Teams

Decision Impact

Reactive, Based on Outdated Info

Atomo / AskMED.ai™

Insight Speed

Minutes – Few Days

Data Access
Unified, Conversational AI, Real-Time
Patient Finding
AI-Powered, Independently Validated ~80% PPV, Proactive
Scope

Comprehensive Queries Across All Disease for 300M+ Americans

Usability

Intuitive Conversational Interface

Decision Impact

Proactive, Insight-Empowered Strategy

Advanced Patient Finding Models

Atomo’s core strengths lie in its advanced Patient Finding Models and the rapid insights delivered by the AskMED.ai platform.

Atomo has developed AI models to identify undiagnosed individuals across several diverse medical conditions. Our proprietary process can be applied to any disease/condition. Successful examples to date include but are not limited to:

  • ATTR-CM (transthyretin amyloidosis)
  • ATTR-PN (polyneuropathies)
  • Alpha-1 antitrypsin deficiency
  • Ankylosing Spondylitis
  • Chronic Granulomatous Disease (CGD)
  • Narcolepsy
  • Primary Aldosteronism (PA)
  • Women’s Hormone Disorder
Start your journey with AskMED.ai today

AskMED.ai ™ Platform

AskMED.ai™ is engineered to deliver rapid, data-driven insights. It significantly reduces data access timelines from months to minutes, enabling more efficient, data-informed decision-making. The platform provides instant conversational access to a vast amount of healthcare data.

Atomo’s patient finding models are being implemented at multiple U.S. and one UK health systems

Enable Timely Interventions

Focus on High Unmet Need Populations

Find Hidden Undiagnosed Patient Populations

Optimize Resource Allocation

Frequently Asked Questions

If you still can’t find the answer you’re looking for, don’t hesitate to contact us.
Contact Us
What are the key healthcare challenges that Atomo's AI solutions address?

Atomo’s AI solutions primarily address the critical healthcare challenges of lack of diagnosis or misdiagnosis, difficulties in healthcare decision-making, and the need to prioritize the vital few individuals who significantly impact healthcare outcomes and costs. We leverage independently validated AI predictive models and our Generative AI-powered platform AskMED.ai™ to tackle these issues.

How does Atomo help identify misdiagnosed and undiagnosed patients?

Atomo’s independently validated AI-powered Patient Finding Solution utilizes machine learning on large-scale healthcare data to identify individuals with specific diseases or conditions who are currently undiagnosed. Our models have demonstrated a high positive predictive value (PPV) of approximately 80% in finding these “hidden patients”. This enables earlier diagnosis and intervention, leading to improved patient outcomes and reduced healthcare costs.

A significant portion of individuals with diseases are often undiagnosed or misdiagnosed, leading to poorer health outcomes and higher healthcare costs. Our solution has been independently validated across several NIH Grants and major peer-reviewed medical journals

What is AskMED.ai™ and how does it improve healthcare decision-making?

AskMED.ai™ is Atomo’s Generative AI-powered platform designed to provide rapid, data-driven healthcare insights. By analyzing vast amounts of data, including healthcare encounter data on over 300 million Americans and over 2.5 million PubMed publications, AskMED.ai™ significantly reduces the time required for analysis from months to minutes or days. This empowers biopharma executives, healthcare practitioners, and health systems to make faster, more informed decisions regarding healthcare priorities, patient management, and treatment strategies.

YourWhat types of data does the AskMED.ai ™ platform analyze?
Atomo’s AskMED.ai™ platform analyzes several key types of data, including over 7 years of Clarivate healthcare encounter data on over 300 million Americans, over 2.5 million commercially available PubMed publications, and Atomo’s proprietary predictive modeling databases. Additionally, users can load and query their own PDF documents within the platform.
How quickly can AskMED.ai™ deliver healthcare insights?

AskMED.ai™ delivers healthcare insights with remarkable speed, reducing typical analytics processes from 90 to 430 days down to just seconds to 28 days depending on the complexity of the analysis. This time compression allows for much faster access to critical information and enables timely action.

Who are the primary users of Atomo's solutions?

Atomo’s AI solutions are primarily designed for biopharma executives, healthcare practitioners (physicians), and health systems. Each of these stakeholder groups benefits from Atomo’s ability to provide rapid, data-driven intelligence tailored to their specific needs and challenges.

What does Atomo mean by "Prioritizing the Vital Few" in healthcare?
“Prioritizing the Vital Few” refers to Atomo’s ability to identify the 5% of individuals with high unmet needs who are likely to utilize 50% of future healthcare resources if timely interventions are not implemented.

We also help identify the 5% of healthcare practitioners who treat 50% of the patients with a specific disease. This focus allows for targeted and impactful interventions.

How does Atomo ensure the accuracy and reliability of its AI models, especially its Generative AI?
Atomo ensures the accuracy and reliability of its proprietary AI models through independent validation, including multiple NIH grants and publications in leading peer-reviewed medical journals. For our Generative AI solutions, we have implemented a testing harness that routinely tests over 100,000 healthcare prompts for accuracy and minimization of hallucinations. AskMED.ai™ has demonstrated 95% accuracy on prompts to our data sources.

Our predictive patient finding models are built upon large-scale medical knowledge and real-world evidence, undergoing rigorous validation to ensure high accuracy. Routinely, our patient finding models result in an 70-80% Positive Predictive Value (PPV).

What differentiates Atomo's AI solutions from others in the healthcare AI space?
Atomo differentiates itself through its over 30 years of healthcare analytics expertise (since 1995) and 20+ years of experience in developing and implementing AI solutions in healthcare. Our independently proven proprietary AI predictive models, validated by NIH and peer-reviewed publications, are a key differentiator. Unlike many others, our AskMED.ai™ platform is already deployed and delivering value with a user interface specifically designed for healthcare professionals. We focus on implementation and validated results, not just theoretical capabilities.
Has Atomo's technology been validated by external organizations?
Yes, Atomo’s technology and solutions have been independently validated through multiple NIH grants, including one NHLBI Grant where Atomo is the Principal Investigator. Our research has been published in several leading peer-reviewed medical journals, such as Lancet Digital Health, Nature Digital Medicine, and Circulation.
Can you provide examples of how Atomo's solutions are used in the real world?
Atomo’s solutions are being implemented with paying clients in the biopharma and health systems verticals. For biopharma, AskMED.ai™ can provide rapid market insights, identify patients for screening and evaluation, and aid in real-world evidence generation.

For health systems, our tools help proactively identify at-risk populations, streamline the integration of new clinical guidelines, and enable more effective population health management.

How does Atomo ensure the explainability of its AI insights?

Atomo is committed to providing explainable AI results through transparency, validation, and clinical contextualization. Our AI architecture incorporates interpretable models, provides feature importance analysis, utilizes counterfactual explanations, and offers interactive visualization tools. All models undergo rigorous clinical validation with healthcare professionals. We also provide healthcare-specific AI literacy training and feedback mechanisms to ensure effective interpretation and trust in AI-generated insights.

I am a biopharma executive. How can Atomo help my organization?
Atomo can provide rapid, data-driven intelligence to significantly reduce market research time and identify timely new opportunities for biopharma organizations. Our solutions can help you understand disease prevalence, identify high-prescribing physicians, and locate undiagnosed patients who could benefit from your therapies, thereby expanding your treatable market. AskMED.ai™ can also accelerate real-world evidence generation to complement clinical trial results.
As a healthcare practitioner, how can AskMED.ai™ assist me?

AskMED.ai™ enables healthcare practitioners to quickly analyze healthcare encounter data and other medical knowledge to uncover undiagnosed patients and gain timely, personalized insights. This can lead to earlier and more accurate diagnoses, better clinical decisions, and improved patient outcomes. You can ask complex clinical questions in natural language and receive answers in seconds, allowing you to act proactively with your patient population.

How can our health system benefit from partnering with Atomo?
Atomo helps health systems achieve faster adoption of new guidelines, more efficient patient stratification, and improved and timely population health management. Our predictive tools proactively identify at-risk populations, and AskMED.ai™ streamlines the analysis of healthcare encounter data to uncover trends and opportunities for intervention, leading to better resource allocation and improved patient outcomes across your network.